Trials & R&D · first seen 2h ago, updated 2h ago

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

1 outlet GLP-1 & obesity drugs Eli Lilly

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Summary from CNBC Health & Science.

Coverage 1 article · 1 outlet

CNBC Health & Science 2h ago
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s